[The efficacy of intra-peritoneal chemotherapy for the patients with cytology positive gastric cancer].
In this study, we assessed efficacy of repeated intra-peritoneal chemotherapy with CDDP for patients with cytology positive gastric cancer. The median survival time was 338 days, 1-year survival was 60% and 2-year survival was 45% of the patients. The POCY1 patients with repeated intra-peritoneal chemotherapy yielded a tendency to extend the survival rate than the patients without repeated intra-peritoneal chemotherapy (p = 0.06). But, no differences were found between the survival rate of P1CY1 patients with or without repeated intra-peritoneal chemotherapy. The patients using more than 3 anti-cancer drugs yielded a tendency to have a better prognosis than the patients using 2 or less anti-cancer drugs (p = 0.09). There was a possibility to which the multidiscipline treatment was effective for the POCY1 gastric cancer patients.
Katayanagi
Sou
S
Dept. of Surgery, Tokyo Medical University.
Sudo
Hideo
H
Suda
Takeshi
T
Hibi
Yasuhiro
Y
Takagi
Yu
Y
Tsuchida
Akihiko
A
Tatsuya
Aoki
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D005260:Female; D005743:Gastrectomy; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D009366:Neoplasm Seeding; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary*; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D015996:Survival Rate
D000970:Antineoplastic Agents; D002945:Cisplatin